Meda enters into joint venture with Valeant
Meda, of Sweden, and US-based Valeant Pharmaceuticals International are to form joint ventures in Australia, Canada and Mexico to develop, market and commercialise certain current and future products. The joint ventures will be majority owned by Meda and Valeant will own a minority interest.
Meda, of Sweden, and US-based Valeant Pharmaceuticals International are to form joint ventures in Australia, Canada and Mexico to develop, market and commercialise certain current and future products. The joint ventures will be majority owned by Meda and Valeant will own a minority interest.
The joint ventures will pursue the regulatory filings and manage the commercialisation of the products and Valeant will participate in a profit share. They will initially include products such as Sublinox (treatment of insomnia) and flupertine (pain treatment), with the option to include additional products in the future.
"We are very pleased to be able to join Valeant in the creation of these three joint ventures," said Ander Lonner, Meda ceo. "Long-term partnerships are a fundamental cornerstone of Meda's strategy and I believe that this collaboration will yield long-term benefits for both companies."